Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Neurocrine Biosciences Inc NBIX

Healthcare Biotechnology
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NBIX)

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

PR Newswire November 7, 2024

Neurocrine Biosciences to Participate at Investor Conferences in November

PR Newswire November 5, 2024

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

PR Newswire November 4, 2024

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

PR Newswire November 4, 2024

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

PR Newswire October 30, 2024

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

PR Newswire October 9, 2024

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

PR Newswire September 30, 2024

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

PR Newswire September 19, 2024

Neurocrine Biosciences Provides Update on ERUDITE(TM) Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

PR Newswire September 12, 2024
View More News ››

Opinion & Analysis (NDAQ:NBIX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NBIX)

Neurocrine Biosciences to Participate at Investor Conference

Just In: $NBIX Neurocrine Biosciences to Participate at Investor Conferences in SeptemberNeurocrine Biosciences to Participate at...
whytestocks - August 28, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Poised for Continued Gr

http://beyondspx.com/2024/08/01/neurocrine-biosciences-nasdaqnbix-poised-for-continued-growth-as-pipeline-advances-and-commercial...
MikeTester - August 2, 2024

And Soros Buys In?

http://www.gurufocus.com/StockBuy.php?symbol=NBIX
scissors14 - June 29, 2006

Pfizer Rejects Indiplon

U.S. Equity News: AstraZeneca Cholesterol Drug Effective and Abbott Phase III Data Jun 26, 2006 (M2 PRESSWIRE via COMTEX News Network...
scissors14 - June 29, 2006

Clinical trails show

San Diego-based Neurocrine Biosciences (NASDAQ: NBIX) says clinical trials show its new drug can reduce the size of inoperable advanced...
SCCNewsServices - April 19, 2000
View more Bullboard ››

Indiva Ltd

Indiva Ltd

Indiva Limited, through its indirect wholly owned subsidiary, Indiva Inc., is a Canada-based producer of cannabis servicing ...
View More »